2022 World Conference on Lung Cancer (ePosters)-EP10.01-011. Prognostic Impact of Body Composition Phenotypes in Non-small Cell Lung Cancer Patients Receiving First-Line Pembrolizumab

EP10.01-011. Prognostic Impact of Body Composition Phenotypes in Non-small Cell Lung Cancer Patients Receiving First-Line Pembrolizumab

Back to course

Pdf Summary

This study aimed to investigate the impact of body composition on the response to immunotherapy in non-small cell lung cancer (NSCLC) patients receiving first-line Pembrolizumab. The researchers performed a retrospective review of 102 patients treated with Pembrolizumab and analyzed their body composition using computed tomography (CT) scans.<br /><br />The results showed that skeletal muscle wasting was frequently observed in NSCLC patients receiving Pembrolizumab, regardless of their body mass index (BMI). Furthermore, the study suggested a potential interaction between body composition and the immune system, which may impact the survival of these patients. Additional analyses are underway in this cohort of patients to further investigate the relationship between clinical, biological, and preclinical factors.<br /><br />The baseline characteristics of the patients were also described. More than a quarter of the patients were overweight or obese, and a significant proportion of them met the criteria for sarcopenia and myosteatosis, which occur across the BMI spectrum. Sarcopenia and myosteatosis were more prevalent in patients with poor performance status.<br /><br />In terms of survival outcomes, the median overall survival was 17.2 months. Higher subcutaneous adipose tissue (SAT) and a higher visceral adipose tissue (VAT)/skeletal muscle area (SMA) ratio were significantly associated with poorer overall survival. A cut-off value for the VAT/SMA ratio was determined using a receiver operating characteristic (ROC) curve.<br /><br />Overall, these findings highlight the importance of considering body composition as a modulator of response to immunotherapy in NSCLC patients. Understanding the relationship between body composition and immunotherapy outcomes may help guide clinical and therapeutic decision-making. Further research is needed to gain a more comprehensive understanding of these associations and their implications in clinical practice.

Asset Subtitle

Ilaria Trestini

Meta Tag

Speaker Ilaria Trestini

Topic Palliative and Supportive Care

Keywords

body composition

immunotherapy

non-small cell lung cancer

NSCLC

Pembrolizumab

skeletal muscle wasting

computed tomography

BMI

immune system

survival outcomes